



FINAL REPORT

| | | | | |
|-----------------|---------------------------------|-----------|-----------------------|------------------------------|
| Bill No. | : MGMWPR240088410 | Bill Date | : 03-10-2024 14:38 | |
| Patient Name | : MRS. LALITA RAVINDRA LOKHANDE | | UHID | : MGM16035596 |
| Age / Gender | : 68 Yrs 2 Mth / FEMALE | | Patient Type | : IPD If PHC : |
| Ref. Consultant | : DR.K. RAJMOHAN | | Ward | : Single A/C Unit- 8th Floor |
| Sample ID | : MGM24147589 | | Current Bed | : 806 |
| IP Number | : MGMIP2406662 | | Reporting Date & Time | : 06-10-2024 13:25 |
| | | | Receiving Date & Time | : 03/10/2024 15:13 |

Microbiology Report

BLOOD - C/S - 2 - BAC ALERT

Specimen : Blood
Site : Peripheral site I & II

Organism : Escherichia coli

| ANTIBIOTICS | INTERPRETATION | MIC |
|--------------------------------|----------------|----------------|
| Amikacin | SENSITIVE | 2 |
| Amoxicillin/Clavulanic acid | RESISTANT | >=32 |
| Cefotaxime | RESISTANT | Disc diffusion |
| Ceftriaxone | RESISTANT | >=64 |
| Cefuroxime | RESISTANT | >=64 |
| Cefoperazone | RESISTANT | Disc diffusion |
| Ceftazidime | INTERMEDIATE | Disc diffusion |
| Gentamicin | SENSITIVE | <=1 |
| Netilmicin | SENSITIVE | Disc diffusion |
| Ciprofloxacin | INTERMEDIATE | Disc diffusion |
| Oflloxacin | INTERMEDIATE | Disc diffusion |
| Levofloxacin | INTERMEDIATE | Disc diffusion |
| Trimethoprim/Sulphamethoxazole | RESISTANT | Disc diffusion |
| Piperacillin/Tazobactam | SENSITIVE | <=4 |
| Cefepime | SENSITIVE | 1 |
| Cefaperazone/Sulbactam | SENSITIVE | Disc diffusion |
| Ticarcillin/Clavulanic acid | SENSITIVE | Disc diffusion |
| Nitrofurantoin | SENSITIVE | Disc diffusion |
| Cefuroxime Axetil | RESISTANT | >=64 |
| Fosfomycin | SENSITIVE | <=16 |

Method :- Culture- Aerobic by Automated BACT/ ALERT 3D. Identification done by Biochemical reactions / Automated Vitek-2 . Antimicrobial sensitivity by automated Vitek -2 / conventional methods/estrips.

Note :-

- Result of culture and antimicrobial susceptibility test need to be correlated clinically.
- Previous history of antibiotic usage may influence the growth of microorganisms in vitro.
- Antibiotic susceptibility done as per revised CLSI Guidelines.

Clinical Reference :

- CLSI: Performance standards for Antimicrobial Susceptibility Testing.

End of the Report